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Predicting daily step activity  1 
 2 
Timed walking tests correlate with daily step activity in individuals with stroke. 3 
 4 
Preliminary data were presented at the Australian Physiotherapy Association 5 
Conference Week, Cairns, Australia, October 2007. 6 
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Timed walking tests correlate with daily step activity in individuals with stroke. 15 
 16 
Abstract 17 
 18 
Objectives: The aim of this study was to examine the relationship between four 19 
clinical measures of walking ability and the outputs of the StepWatch Activity 20 
Monitor in participants with stroke. 21 
Design: Correlational study 22 
Setting: Clinic and participants’ usual environments 23 
Participants: 50 participants more than six months following stroke were 24 
recruited. Participants were all able to walk independently, but with some 25 
residual difficulty. 26 
Interventions: Not applicable. 27 
Main Outcome Measures: Rivermead Mobility Index (RMI), Rivermead Motor 28 
Assessment (RMA), Six Minute Walk Test (6MWT), 10 Metre Walk Test (10MWT), 29 
StepWatch outputs (based on daily step counts and stepping rates). 30 
Results: The correlations between the RMA and all StepWatch outputs were low 31 
(ρ=0.36-0.48, p<0.05), as were the majority for the RMI (ρ=0.31-0.52, p<0.05). 32 
The 10MWT and 6MWT had moderate to high correlations (ρ=0.51 to 0.73, 33 
p<0.01) with the majority of StepWatch outputs. Multiple regression showed that 34 
the 6MWT was the only significant predictor for the majority of StepWatch 35 
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outputs, accounting for between 38% and 54% of the variance. Age and the RMI 36 
were further significant predictors of one and two outputs respectively. 37 
Conclusions: The 6MWT has the strongest relationship with the StepWatch 38 
outputs and may be a better test than the 10MWT to predict usual walking 39 
performance. However, it should be remembered that the 6MWT explains only 40 
half of the variability in usual walking performance. Thus, activity monitoring 41 
captures aspects of walking performance not captured by other clinical tests and 42 
should be considered as an additional outcome measure in stroke rehabilitation. 43 
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Stroke is the most common cause of severe disability in adults,1 with persistent 50 
physical disability reported in 50-65% of individuals who survive stroke.1-3 51 
Although as many as 70% are able to walk independently following 52 
rehabilitation,3, 4 it appears that only a small percentage of these individuals are 53 
able to walk functionally in the community.5, 6 This difference may reflect a 54 
discrepancy between testing walking in a clinical environment and monitoring 55 
usual walking in natural environments as has been suggested by the 56 
International Classification of Functioning, Disability and Health. 7  57 
 58 
There are a range of clinical tests available to assess walking following stroke, 59 
many of which have good psychometric properties and assess wider aspects of 60 
gait thought to relate to walking in community environments.8 Some tests 61 
involve direct therapist observation of walking, of which an aspect is then graded 62 
or measured. Examples include the Ten Metre Walk Test (10MWT),9 the Six 63 
Minute Walk Test (6MWT)10 and the Rivermead Motor Assessment (RMA).11 64 
Other outcome measures rely on patient self-report of usual function, such as 65 
the Rivermead Mobility Index (RMI)12 and the Functional Ambulation 66 
Categories.13 67 
 68 
The advantage of the directly observed tests is their standardized nature, but 69 
they may be more reflective of best performance rather than usual performance. 70 
For example, self selected gait speed (measured by the 10MWT) is a global 71 
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indicator of physical functioning14 and can discriminate between different 72 
categories of community ambulation.6 However, community ambulation can be 73 
achieved by individuals with stroke who have low gait velocities suggesting that 74 
gait velocity alone is not sufficient as a measure of community ambulation.6 Self 75 
report measures, on the other hand may ask about usual performance, however 76 
they depend on the accuracy of a patient’s perception, cognition and 77 
communication.15, 16 Indeed, a recent study has shown that individuals with 78 
stroke have a higher subjective report of physical activity and exercise than is 79 
found on objective testing.17  80 
 81 
Activity monitors are one way of monitoring usual walking performance in natural 82 
environments as they can be worn during everyday activities over extended 83 
periods. The typical output is counts with respect to time, which can give 84 
information about amount, rate and patterns of activity. An activity monitor that 85 
has been used to investigate ambulatory activity following stroke is the 86 
StepWatch Activity Monitora.18-20 The monitor contains a custom sensor that uses 87 
a combination of acceleration, position and timing to determine the number and 88 
rate of steps taken. The StepWatch has been shown to have criterion validity18, 21 89 
and is reliable19, 22 for step counting in individuals with stroke. The output of the 90 
StepWatch is based on the number of steps taken on one leg, which is doubled 91 
to represent steps taken on both legs19, 20, 23, 24. The most commonly reported 92 
output of the StepWatch, mean steps per day,19, 20, 23, 25 correlates moderately 93 
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with self selected gait speed (r=0.55)20 and scores on the Functional 94 
Independence Measure (r=0.62)23 and Berg Balance Scale (r=0.58)20 in patients 95 
with stroke. Recent research has also shown that mean steps/day shows a low 96 
correlation to peak exercise capacity (r=0.316)24 but is not related to self-97 
reported fatigue severity24, 26 or economy of gait24. 98 
 99 
Many other outputs of the StepWatch are available, which include calculations 100 
based on rate of stepping. The peak activity index is the average step rate of the 101 
fastest 30 minutes over 24 hours, regardless of when they occurred. Sustained 102 
activity measures are also available for 1, 5, 20, 30 and 60 minutes and are 103 
calculated by scanning the accumulated 24 hour data to determine the maximum 104 
number of steps taken during continuous intervals of 1, 5, 20, 30 and 60 105 
minutes. The number of steps at high (above 60 steps/min), medium (between 106 
30 and 60 steps/min) and low (below 30 steps/min) step rates can also be 107 
calculated. We have recently shown good test-retest reliability for a number of 108 
these additional outputs in individuals with stroke, particularly peak activity index 109 
and maximum number of steps in 5 and 1 minutes.22 However, the relationship 110 
between commonly used clinical measures of walking ability and these additional 111 
StepWatch outputs has not been studied. 112 
 113 
Thus the aims of this study were to determine the strength of the relationship 114 
between commonly used clinical tests of walking ability and the available 115 
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StepWatch outputs and in particular, determine how well clinical walking tests 116 
predict ambulatory activity in natural environments as measured by the 117 
StepWatch. Self selected gait speed was measured by the 10MWT and gait 118 
endurance was measured by the 6MWT, both of which are used commonly 8 and 119 
have good psychometric properties.10  120 
 121 
We chose the RMI to capture self reported mobility as six of the 15 items report 122 
on walking situations and it has good psychometric properties.8 The Rivermead 123 
Motor Assessment (RMA) was also selected as five of the 13 items directly test 124 
walking conditions.8 Both the RMI and RMA reflect a breadth of walking 125 
conditions, such as walking over uneven surfaces and walking outside that are 126 
not evaluated by the commonly used timed walking tests. We hypothesized that 127 
performance during these common walking conditions may have a stronger 128 
relationship to usual walking activity in natural settings than do the timed 129 
walking tests.  130 
 131 
Methods  132 
 133 
Participants 134 
 135 
A power calculation based on mean steps/day (standard deviation of 4390 136 
steps/day) and the 6MWT (standard deviation of 124 metres) from pilot data 137 
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(n=16) suggested that a sample size of 24 would achieve 99% power (=0.05)27 138 
for a single correlation. To ensure adequate power for a multiple regression 139 
analysis, a convenience sample of 50 individuals with chronic stroke was 140 
recruited based on formulae by Green (minimum of 46 participants for 5 141 
predictors and estimated multiple correlation of 0.50).28 Participants were 142 
recruited from the hospital stroke service and local and newspaper advertising 143 
and were eligible for inclusion if they were at least six months post stroke and 144 
were able to walk independently, but with some residual difficulty, confirmed by 145 
a score of less than 2 on at least one of the walking items (a, d, e, g, h, or i) of 146 
the physical functioning scale of the SF-36.29 Participants also had to walk in the 147 
community at least once a week, determined by response to the question “How 148 
many times do you walk past your letterbox, on average in one week?” 149 
Individuals were excluded if they had fallen more than twice in the previous six 150 
months, had another serious health problem affecting walking (e.g. 151 
musculoskeletal or cardiovascular condition) or if they were unable to complete 152 
the testing for another reason (e.g. inability to follow instructions).  153 
 154 
Testing Protocol 155 
 156 
The study was approved by the Northern Regional Ethics Committee. All 157 
participants attended a rehabilitation clinic for initial testing and gave written 158 
informed consent. The clinical tests were administered by one examiner. The 159 
  9 
RMI is a self report of ability to perform up to 15 mobility items, with answers 160 
given of either “yes” or “no”. The highest score of 15 indicates an ability to climb 161 
up and down four steps with no rail and run 10 metres. The RMA was tested in a 162 
clinic and outside environment and patients were scored on each of the 13 items, 163 
based on their ability to perform the mobility task. The maximum score of 13 164 
indicates an ability to run 10 metres and hop on the affected leg five times. Self 165 
selected gait speed was measured at comfortable pace over 10 metres (10MWT) 166 
and gait endurance was tested by the 6MWT, both following standardised 167 
protocols.30 168 
 169 
A StepWatch was calibrated and attached to the lateral side of the ankle of the 170 
non-paretic leg with a strap or cuff. The monitor has an infrared light that flashes 171 
with every step, which were matched to a manual count of steps during walking 172 
five metres at each of three walking speeds (fast, slow and self selected). The 173 
sensitivity and cadence settings were adjusted, if necessary, until the flashes 174 
corresponded exactly with the manual count during the three walking speeds.  175 
 176 
Participants were instructed to wear the monitor for the next three days, 177 
removing it for sleeping and showering. Participants were given an instruction 178 
sheet with details about the care of the StepWatch and a follow up appointment 179 
was made to pick up the monitor. Data were exported to Excelb where the 180 
number of steps detected over a 24 hour period was doubled to obtain steps/day 181 
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for both legs. A sub-group of these patients (n=37) also agreed to participate in 182 
further data collection for a larger study of reliability testing, results of which are 183 
in press.22 184 
 185 
Statistical analyses 186 
 187 
Variables were tested for normality using the Shapiro-Wilk statistic. The level of 188 
association between the variables was assessed using Pearson’s correlation 189 
coefficient for normally distributed variables or Spearman’s rank correlation 190 
coefficient for variables without a normal distribution, with significance accepted 191 
at the 0.05 level. A correlation above 0.90 was interpreted as very high, 0.70-192 
0.89 as high, 0.50-0.69 as moderate, 0.30-0.49 as low and less than 0.29 as 193 
little, if any correlation.31 Age and gender were also tested for correlation with 194 
StepWatch outputs as they were potentially confounding factors. A forward linear 195 
multiple regression analysis was performed for each of the significant variables 196 
from the correlation entered as independent variables and the StepWatch 197 
outputs as the dependent variables. All calculations were performed using SPSS.c 198 
 199 
Results 200 
 201 
Fifty participants enrolled in the study. Forty-nine of the 50 participants, mean  202 
SD age of 67.4  12.5 years and six to 219 months following stroke, completed 203 
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the study (Table 1). The remaining participant did not have three complete days 204 
of data so was excluded from the analysis. There were 29 men and 20 women. 205 
Eighteen participants had right sided paresis. The median score on the physical 206 
functioning index of the SF-3629 was 18 (range 10 to 29), where the maximum 207 
score of 30 indicates no limitations with all items, including walking more than a 208 
mile, climbing several flights of stairs and running and a score of 10 indicates 209 
significant limitations with all items. All participants walked independently with an 210 
assistive device, if necessary. However, median scores on the RMI and RMA 211 
indicated that the participants had difficulty with higher level mobility tasks such 212 
as running, hopping and climbing up and down steps without a handrail. The 213 
mean steps/day showed a wide variation between participants from a low of 214 
1225 steps/day to a high of 21273 steps/day (Table 1). However, the median of 215 
4765 steps/day in this study was lower than 6565 steps/day reported by 216 
Bohannon32 for apparently healthy adults over 65 years. 217 
 218 
Only two clinical tests (10MWT and 6MWT) and three StepWatch outputs 219 
(number of steps at a low rate, peak activity index and highest step rate in 1 220 
minute) were distributed normally. Thus, the majority of correlations shown in 221 
Table 2 use Spearman’s correlation coefficient. Gender showed no correlation 222 
with any of the StepWatch outputs but age showed a significant but low 223 
correlation (ρ=-0.33, p<0.05) with number of steps at a high rate and highest 224 
step rate in 60 minutes. The correlations between the RMA and all the 225 
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StepWatch outputs were less than 0.50, as were the majority for the RMI. There 226 
were two moderate correlations between StepWatch outputs and the RMI; mean 227 
steps/day was positively correlated (ρ=0.51, p<0.01) and percentage of time 228 
with no steps was negatively correlated (ρ=-0.52, p<0.01). The 10MWT had 229 
moderate correlations with the majority of StepWatch outputs, with the highest 230 
step rate in one minute reaching a high level of correlation (r=0.71, p<0.01). 231 
The 6MWT reached at least a moderate level of correlation with all StepWatch 232 
outputs, with peak activity index (r=0.72, p<0.01) and highest step rate in one 233 
minute (r=0.73, p<0.01) reaching a high level of correlation. 234 
 235 
Regression analysis using StepWatch outputs as the dependent variables and 236 
age, RMI, RMA, 10MWT and 6MWT as the independent variables showed that for 237 
the majority of StepWatch outputs, the 6MWT was the single most significant 238 
predictor (Table 3). The 6MWT accounted for between 30% (for number of steps 239 
at a low rate) and 54% (for mean steps/day) of the variance in the StepWatch 240 
outputs. For three outputs (highest step rate in 60 minutes, percentage of time 241 
with no steps and number of steps at a low rate), other variables made an 242 
independent contribution to the variance. Age made a significant contribution to 243 
the variance in highest step rate in 60 minutes over and above that of the 244 
6MWT, increasing the explained variance from 44% to 49%. The 6MWT and the 245 
RMI independently contributed to both the percentage of time with no steps and 246 
the number of steps at a low rate. For the percentage of time with no steps, the 247 
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addition of RMI increased the explained variance from 40% to 47%. For the 248 
number of steps at a low rate, the addition of the RMI increased the explained 249 
variance from 30% to 36%. 250 
 251 
Discussion 252 
 253 
The aims of this study were to determine the strength of the relationship 254 
between commonly used clinical tests of walking ability and the available 255 
StepWatch outputs and in particular determine how well clinical walking tests 256 
predict ambulatory activity in natural environments. We found that both the 257 
10MWT and the 6MWT were, in general, more highly correlated with the 258 
StepWatch outputs than were either the RMI or the RMA. However, on 259 
regression analysis, the 6MWT was the only significant predictor for all but three 260 
of the StepWatch outputs, with the 10MWT making no further independent 261 
contribution to the variance.  262 
 263 
The 6MWT is seen as a measure of submaximal exercise performance.33 Thus, 264 
the ability of the 6MWT to predict variations in walking performance in a natural 265 
environment is perhaps not unexpected. It is possible that distance on the 6MWT 266 
could be used as a quick test to estimate usual walking activity. From our data, 267 
the 95% confidence interval for the regression equation for an individual who 268 
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achieved a distance of 153 metres would suggest that they might average 269 
between 3078 and 5231 steps/day. 270 
 271 
Self selected gait speed measured over a short distance (eg 10MWT) is the most 272 
commonly used test to assess walking ability in a clinical situation.8 It is 273 
extremely quick and easy to administer, and from both this study and others20, 34 274 
is moderately correlated to mean steps/day, both in participants with stroke 275 
(r=0.55)20 and neurological disorders (r=0.58).34 However, our data suggests 276 
that the 6MWT may be a better clinical test to use to predict usual walking 277 
performance. The 10MWT nevertheless is very highly correlated with the 6MWT 278 
and still has a role, particularly if it is not possible to test walking for six minutes. 279 
 280 
Both the RMI and RMA showed a low correlation with the majority of StepWatch 281 
outputs. These data are similar to a previous study of participants with 282 
neurological disorders which showed a low correlation between mean steps/day 283 
and the RMI (r=0.49).34 One explanation for this finding is that both the RMI and 284 
the RMA assess mobility, rather than walking per se. For example, they both 285 
assess bed mobility and transfer skills. They also assess wider aspects of 286 
walking, such as stair climbing, walking outside and walking over uneven 287 
surfaces, which are thought to be important aspects of usual walking 288 
performance.35 Although the StepWatch accurately identifies steps under these 289 
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walking conditions,21 it does not distinguish between these different aspects of 290 
walking, which might explain the lower correlation. 291 
 292 
However, the RMI, which measures self reported mobility, was an independent 293 
predictor of two StepWatch outputs (percentage of time with no steps and 294 
number of steps at a low stepping rate). Both of these outputs reflect reduced 295 
levels of walking activity. This result suggests that patients’ perception of 296 
reduced mobility may be able to predict aspects of usual walking performance. 297 
Although, self reported measures of physical activity have been shown to be 298 
inflated when compared to mean steps/day,17 it is still possible that some 299 
individuals with stroke voluntarily restrict activity if they have a low perception of 300 
their functional ability.36 However, whether the perception of reduced mobility is 301 
a causative factor in the low levels of activity or a consequence of it, is not 302 
certain.  303 
 304 
In addition to the 6MWT, age was an independent predictor of, and inversely 305 
related to, the highest step rate in 60 minutes. This StepWatch output measures 306 
the highest step rate in a continuous 60 minute period and might be expected to 307 
decrease with reduced exercise performance, as measured by the 6MWT.37 308 
However the finding that age also makes an independent contribution was 309 
unexpected as age has not been shown to relate to walking speed in adults with 310 
chronic stroke.38 This finding suggests that the level of sustained activity 311 
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decreases with age in people with chronic stroke over and above that which can 312 
be attributed to decreased endurance. 313 
 314 
Half of the variability in StepWatch outputs of usual walking performance is not 315 
accounted for by the clinical walking tests. As community walking is related to 316 
other physical characteristics in addition to gait speed,6, 39 it is also possible that 317 
physical factors such as balance,40 fitness,41 use of assistive devices and motor 318 
function may also affect usual walking performance. It is also likely that 319 
behavioural, personal, environmental and social factors will have some impact on 320 
walking performance in natural environments,14, 42 but there is little research in 321 
this area. Until these factors are identified, there would seem to be a place for 322 
the inclusion of activity monitoring as an outcome measure during stroke 323 
rehabilitation.  324 
 325 
Limitations of this study are the selected nature of the participants, which may 326 
not generalize to the entire stroke population. Furthermore, participants may 327 
have changed their walking activity in their own environment as a result of the 328 
monitoring, thus not giving completely accurate data on usual performance. 329 
 330 
In addition, this study was adequately powered to detect a correlation coefficient 331 
r>0.5 in the regression analysis, but more subjects would have been needed to 332 
detect a smaller effect size28, such as shown by the lower correlations between 333 
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both the RMI and the RMA and the SAM outputs. However, the question remains, 334 
whether such a level of correlation should be considered to be clinically 335 
significant.  336 
 337 
It should be acknowledged that while the StepWatch is an objective measure of 338 
usual walking, the information gained is limited to amount and rate of walking 339 
and patterns of activity. The StepWatch cannot, for instance, give information 340 
about functional goals achieved or effectiveness and energy cost of walking.  341 
 342 
Conclusions 343 
 344 
The 6MWT is the clinical test with the strongest relationship with the StepWatch 345 
outputs. Thus the 6MWT may be a better test than the 10MWT to predict usual 346 
walking performance, however, it should be remembered that half of the 347 
variability in usual walking performance is not explained by either clinical walking 348 
test. Thus, activity monitoring detects aspects of usual walking performance in 349 
participants with stroke not captured by clinical tests and should be considered 350 
as an additional outcome measure for rehabilitation programmes. 351 
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Table 1. Study Sample Characteristics
Mean ± SD Median Range
Demographics
Age (years) 67.4 ± 12.5 38 - 89
Months since stroke 66 ± 61 6 - 219
SF-36 score 18 10 - 29
Clinical Test 
10MWT (m/s) 0.67 ± 0.32  0.12 - 1.42
6MWT (m) 230 ± 121  42 - 568
RMA 10 5 - 13
RMI 13 6 - 15
StepWatch Outputs
Mean steps/day 4765  1225 - 21273
Percentage of time with no steps (%) 83%  53 - 96
Number of steps at low rate (<30 steps/minute) 2334 ± 565  493 - 5331
Number of steps at high rate (>60 steps/minute) 655  0 - 10590
Peak activity index (steps/min) 58.7 ± 10.6  17 - 112
Highest step rate in 60 minutes (max 60) (steps/min) 18.7  5 - 89
Highest step rate in 1 minute (max 1) (steps/min) 81.5 ± 11.1  23 - 128478 
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Table 2. Correlation coefficient* for StepWatch outputs and clinical gait tests and age.
StepWatch output RMI RMA 10MWT 6MWT Age
Mean steps/day 0.51 0.47 0.55 0.67 -0.29†
Percentage of time with no steps -0.52 -0.47 -0.41 -0.57 NS
Number of steps at low rate (<30 steps/minute) 0.47 0.44 046* 0.58* NS
Number of steps at high rate (>60 steps/minute) 0.31† 0.42 0.54 0.60 -0.33†
Peak activity index 0.37 0.40 0.64* 0.72* -0.28†
Highest step rate in 60 minutes (max 60) 0.46 0.48 0.51 0.59 -0.33†
Highest step rate in 1 minute (max 1) 0.36† 0.41 0.71* 0.73* NS
* indicates use of Pearson's correlation coefficient. All other correlations use Spearman's correlation coefficient.
† correlation is significant at the 0.05 level. All other correlations are significant at the 0.01 level.
NS = not significant  482 
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Table 3. Stepwise linear regression models of selected StepWatch outputs
StepWatch Output/Predictors
Regression 
coefficients R
2
R
2 
change p
adjusted 
R
2
constant
Mean steps/day
6MWT 26.2 0.54 0.000 0.53 159.7
Percentage of time with no steps (%)
6MWT 0.000 0.40 0.000 0.38 0.92
6MWT & RMI 0.000 / -0.014 0.46 0.06 0.000 0.44 1.07
Number of steps at low rate (<30 steps/minute)
6MWT 5.39 0.33 0.000 0.32 1092
6MWT & RMI 3.92 / 186.5 0.41 0.08 0.000 0.39 -908.4
Number of steps at high rate (>60 steps/minute)
6MWT 12.2 0.46 0.000 0.45 -625.5
Peak activity index (steps/min)
6MWT 0.126 0.51 0.000 0.50 29.7
Highest step rate in 60 minutes (max 60) (steps/min)
6MWT 0.090 0.44 0.000 0.43 4.05
6MWT & Age 0.082 / -0.312 0.49 0.05 0.000 0.47 26.6
Highest step rate in 1 minute (max 1) (steps/min)
6MWT 0.136 0.54 0.000 0.53 50.3485 
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